Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019 : Friend or Foe?
When the coronavirus disease 2019 (COVID-19) wreaked an unprecedented havoc of an escalating number of deaths and hospitalization in the United States, clinicians were faced with a myriad of unanswered questions, one of the them being the implication of the renin-angiotensin-aldosterone system in patients with COVID-19. Animal data and human studies have shown that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the expression of ACE2. ACE2 is an enzyme found in the heart, kidney, gastrointestinal tract, and lung and is a coreceptor for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV2), the virus responsible for COVID-19. Therefore, one can speculate that discontinuing ACE inhibitor or ARB therapy may lead to decreased ACE2 expression, thereby attenuating the infectivity of SARS-CoV-2, and mitigating the disease progression of COVID-19. However, several studies have also shown that ACE2 exhibits reno- and cardioprotection and preserves lung function in acute respiratory distress syndrome, which would favor ACE inhibitor or ARB therapy. This article is to examine and summarize the 2 opposing viewpoints and provide guideline recommendations to support the use or discontinuation of ACE inhibitors and ARBs in patients with COVID-19.
| Errataetall: |
CommentIn: Cardiol Rev. 2020 Jul/Aug;28(4):161-162. - PMID 32427638 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Cardiology in review - 28(2020), 4 vom: 01. Juli, Seite 213-216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shyh, Grace I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 15.06.2020 Date Revised 03.02.2021 published: Print CommentIn: Cardiol Rev. 2020 Jul/Aug;28(4):161-162. - PMID 32427638 Citation Status MEDLINE |
|---|
| doi: |
10.1097/CRD.0000000000000319 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310759757 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310759757 | ||
| 003 | DE-627 | ||
| 005 | 20231225140802.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CRD.0000000000000319 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310759757 | ||
| 035 | |a (NLM)32496364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shyh, Grace I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019 |b Friend or Foe? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2020 | ||
| 500 | |a Date Revised 03.02.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Cardiol Rev. 2020 Jul/Aug;28(4):161-162. - PMID 32427638 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a When the coronavirus disease 2019 (COVID-19) wreaked an unprecedented havoc of an escalating number of deaths and hospitalization in the United States, clinicians were faced with a myriad of unanswered questions, one of the them being the implication of the renin-angiotensin-aldosterone system in patients with COVID-19. Animal data and human studies have shown that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the expression of ACE2. ACE2 is an enzyme found in the heart, kidney, gastrointestinal tract, and lung and is a coreceptor for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV2), the virus responsible for COVID-19. Therefore, one can speculate that discontinuing ACE inhibitor or ARB therapy may lead to decreased ACE2 expression, thereby attenuating the infectivity of SARS-CoV-2, and mitigating the disease progression of COVID-19. However, several studies have also shown that ACE2 exhibits reno- and cardioprotection and preserves lung function in acute respiratory distress syndrome, which would favor ACE inhibitor or ARB therapy. This article is to examine and summarize the 2 opposing viewpoints and provide guideline recommendations to support the use or discontinuation of ACE inhibitors and ARBs in patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Nawarskas, James J |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng-Lai, Angela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiology in review |d 1997 |g 28(2020), 4 vom: 01. Juli, Seite 213-216 |w (DE-627)NLM09257050X |x 1538-4683 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:4 |g day:01 |g month:07 |g pages:213-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CRD.0000000000000319 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 4 |b 01 |c 07 |h 213-216 | ||